The effect of COX-2 Inhibition on Reducing Central Sensitisation of Pain in Osteoarthritis

King's College London0 个研究点目标入组 16 人开始时间: 2006年2月13日最近更新: 2018年12月4日

试验速览

暂无简介。

•Age > 18 years old • Patient must be right handed • Patients with ACR criteria defined OA of the knee. • All patients must have radiological OA and pain for more than 1 year. • All patients must have given signed informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•History of hypersensitivity to the active substance or to any of the excipients. • Active peptic ulceration or active gastro-intestinal (GI) bleeding. • Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclo-oxygenase-2) inhibitors. • Pregnancy and lactation. • Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score >=10). • Estimated renal creatinine clearance <30 ml/min. • Inflammatory bowel disease. • Congestive heart failure (NYHA II-IV). • Patients with hypertension whose blood pressure has not been adequately controlled. • Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease. - Previous history of cerebrovascular accident or disease of the central nervous system. - Taking any non-specific NSAID. - Any contraindication to fMRI scan such as: 1. patients suffering from claustrophobia 2. patient with magnetic metal implant in the body 3. patient with cardiac pacemaker

发起方